Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$16.57 USD
+0.75 (4.74%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $16.52 -0.05 (-0.30%) 7:14 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.57 USD
+0.75 (4.74%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $16.52 -0.05 (-0.30%) 7:14 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
Zacks News
SenesTech (SNES) to Gain Market With Evolve's Launch on Amazon
by Zacks Equity Research
SenesTech (SNES) looks to leverage the convenience and reach of e-commerce to expand its market share.
Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor
by Zacks Equity Research
Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.
Reasons to Hold Charles River (CRL) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
by Moumi Mondal
Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.
Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst
by Zacks Equity Research
Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.
Here's Why Investors Should Retain ICON (ICLR) Stock Now
by Zacks Equity Research
Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.
Stereotaxis (STXS) Gets CE Recertification for Approved Products
by Zacks Equity Research
Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Boston Scientific (BSX) due to its geographical expansions and impressive acquisitions.
Charles River (CRL) Banks on RMS Growth Amid Competition
by Zacks Equity Research
Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.
Zacks Market Edge Highlights: Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco
by Zacks Equity Research
Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco are part of the Zacks Market Edge blog.
Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial
by Zacks Equity Research
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Reasons to Include Alcon (ALC) in Your Portfolio Right Now
by Zacks Equity Research
New product launches and strong solvency bode well for Alcon (ALC).
5 Top Ranked Strong Buy Growth Stocks for 2024
by Tracey Ryniec
Get double digit earnings growth this year.
Boston Scientific (BSX) Rides on Emerging Markets, MedSurg
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
by Zacks Equity Research
Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.
Globus Medical (GMED) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.
Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes
by Zacks Equity Research
Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.
Here's Why You Should Buy Haemonetics (HAE) Stock Now
by Zacks Equity Research
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).
Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade
by Zacks Equity Research
Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
by Zacks Equity Research
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Abbott's (ABT) share recovery in the Nutrition business buoys optimism.
IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues
by Zacks Equity Research
IDEXX (IDXX) is being hurt by geopolitical instability, including the current war in Ukraine, which has affected supply chain operations globally.
Here's Why Investors Should Buy ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.